Effect of synbiotic therapy on the incidence of ventilator associated pneumonia in critically ill patients: a randomised, double-blind, placebo-controlled trial
| العنوان: | Effect of synbiotic therapy on the incidence of ventilator associated pneumonia in critically ill patients: a randomised, double-blind, placebo-controlled trial |
|---|---|
| المؤلفون: | Susan E. Snape, David J. W. Knight, Vivienne C Weston, Dale Gardiner, Keith Girling, Amanda Banks, Stig Bengmark |
| المصدر: | Intensive Care Medicine. 35 |
| بيانات النشر: | Springer Science and Business Media LLC, 2008. |
| سنة النشر: | 2008 |
| مصطلحات موضوعية: | Dietary Fiber, Male, medicine.medical_specialty, Critical Illness, medicine.medical_treatment, Placebo-controlled study, Critical Care and Intensive Care Medicine, Placebo, Enteral administration, law.invention, Anti-Infective Agents, Double-Blind Method, Randomized controlled trial, law, Intensive care, Internal medicine, medicine, Humans, Prospective Studies, Glucans, Intubation, Gastrointestinal, Mechanical ventilation, business.industry, Probiotics, Incidence (epidemiology), Ventilator-associated pneumonia, Pneumonia, Ventilator-Associated, Middle Aged, medicine.disease, Surgery, Lactobacillus, Female, business |
| الوصف: | To investigate the effect of enteral Synbiotic 2000 FORTE® (a mixture of lactic acid bacteria and fibre) on the incidence of ventilator associated pneumonia (VAP) in critically ill patients. Prospective, randomised, double blind, placebo controlled trial. Tertiary referral centre, general Adult Intensive Care Unit (ICU). 259 enterally fed patients requiring mechanical ventilation for 48 h or more were enrolled. All patients were enterally fed as per a standard protocol and randomly assigned to receive either synbiotic 2000 FORTE® (twice a day) or a cellulose-based placebo for a maximum of 28 days. Treatment group (n = 130) was well matched with placebo group (n = 129) for age (mean 49.5 and 50 years, respectively) and APACHE II score (median 17 for both). Oropharyngeal microbial flora and colonisation rates were unaffected by synbiotics. The overall incidence of VAP was lower than anticipated (11.2%) and no statistical difference was demonstrated between groups receiving synbiotic and placebo in the incidence of VAP (9 and 13%, P = 0.42), VAP rate per 1,000 ventilator days (13 and 14.6, P = 0.91) or hospital mortality (27 and 33%, P = 0.39), respectively. Enteral administration of Synbiotic 2000 FORTE® has no statistically significant impact on the incidence of VAP in critically ill patients. |
| تدمد: | 1432-1238 0342-4642 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d5ad64d2e2045f7bfadc9796289863fc https://doi.org/10.1007/s00134-008-1368-1 |
| حقوق: | CLOSED |
| رقم الأكسشن: | edsair.doi.dedup.....d5ad64d2e2045f7bfadc9796289863fc |
| قاعدة البيانات: | OpenAIRE |
Find this article in full text from Springer Verlag. | تدمد: | 14321238 03424642 |
|---|